lorazepam has been researched along with Behavior Disorders in 31 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| " It offers future studies direction for standardizing lorazepam dosing schedules for catatonia management and exploring neurobiological underpinnings for individual catatonic signs that may be potentially different, given these findings." | 5.62 | Revisiting lorazepam challenge test: Clinical response with dose variations and utility for catatonia in a psychiatric emergency setting. ( Aandi Subramaniyam, B; Muliyala, KP; Reddi, VSK; Suchandra, HH, 2021) |
| "Lorazepam was successfully used, along with electroconvulsive therapy, antipsychotics, and other treatments." | 3.01 | COVID-19 and catatonia: Prevalence, challenges, pathophysiology, and treatment. ( Koola, MM; Mohammadi, T; Oh, J; Pradhan, BK; Sahota, PC, 2023) |
| "Lorazepam 1 to 2 mg was administered in every case, and patients were evaluated at hourly intervals." | 2.67 | Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. ( Furlong, BG; Hildebrand, AM; Mazurek, MF; Rosebush, PI, 1990) |
| "Most cases prove to be due to primary psychiatric disorders, mostly mood disorders, especially mania, rather than schizophrenia." | 2.47 | Psychogenic unresponsiveness. ( Hurwitz, TA, 2011) |
| "Polypharmacy increases the risk of potential drug-drug interactions (pDDIs)." | 1.72 | Clinical significance of potential drug-drug interactions in older adults with psychiatric disorders: a retrospective study. ( Cui, Y; Ding, Y; Ji, M; Liu, Y; Wang, D; Wang, H; Yang, M; Zhang, H; Zhuang, T, 2022) |
| " It offers future studies direction for standardizing lorazepam dosing schedules for catatonia management and exploring neurobiological underpinnings for individual catatonic signs that may be potentially different, given these findings." | 1.62 | Revisiting lorazepam challenge test: Clinical response with dose variations and utility for catatonia in a psychiatric emergency setting. ( Aandi Subramaniyam, B; Muliyala, KP; Reddi, VSK; Suchandra, HH, 2021) |
| "We recommend being alert for catatonia in patients with or without a psychiatric disorder." | 1.36 | [Catatonia]. ( Blom, JD; Bruijn, DJ, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (19.35) | 18.7374 |
| 1990's | 5 (16.13) | 18.2507 |
| 2000's | 6 (19.35) | 29.6817 |
| 2010's | 9 (29.03) | 24.3611 |
| 2020's | 5 (16.13) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y | 1 |
| Yang, M | 1 |
| Ding, Y | 1 |
| Wang, H | 2 |
| Zhang, H | 1 |
| Wang, D | 1 |
| Zhuang, T | 1 |
| Ji, M | 1 |
| Cui, Y | 1 |
| Tiwari, S | 1 |
| Akyuz, E | 1 |
| Das, A | 1 |
| Oh, J | 1 |
| Sahota, PC | 1 |
| Mohammadi, T | 1 |
| Pradhan, BK | 1 |
| Koola, MM | 1 |
| Uguz, F | 1 |
| Kirkas, A | 1 |
| Aksoy, ZK | 1 |
| Yunden, S | 1 |
| Suchandra, HH | 1 |
| Reddi, VSK | 1 |
| Aandi Subramaniyam, B | 1 |
| Muliyala, KP | 1 |
| Lopez, E | 1 |
| Fraile, S | 1 |
| Hidalgo, FJ | 1 |
| García, B | 1 |
| Jørgensen, A | 1 |
| Hansen, BS | 1 |
| Stanislaus, S | 1 |
| Düring, S | 1 |
| Jørgensen, MB | 1 |
| Pinborg, LH | 1 |
| Kondziella, D | 1 |
| Ellini, S | 1 |
| Feki, I | 1 |
| Smaoui, N | 1 |
| Jamoussi, I | 1 |
| Masmoudi, J | 1 |
| Giersch, A | 1 |
| Boucart, M | 1 |
| Elliott, M | 1 |
| Vidailhet, P | 1 |
| Bruijn, DJ | 1 |
| Blom, JD | 1 |
| Swart, GT | 1 |
| Siman, E | 1 |
| Stewart, SL | 1 |
| Hurwitz, TA | 1 |
| Watt, KM | 1 |
| Walgos, J | 1 |
| Cheifetz, IM | 1 |
| Turner, DA | 1 |
| Price, O | 1 |
| Baker, JA | 1 |
| Feinberg, DT | 1 |
| Alexander, J | 1 |
| Tharyan, P | 1 |
| Adams, C | 1 |
| John, T | 1 |
| Mol, C | 1 |
| Philip, J | 1 |
| Trottenberg, T | 1 |
| Volkmann, J | 1 |
| Deuschl, G | 1 |
| Kühn, AA | 1 |
| Schneider, GH | 1 |
| Müller, J | 1 |
| Alesch, F | 1 |
| Kupsch, A | 1 |
| Jhirwal, OP | 1 |
| Kulhara, P | 1 |
| Basu, D | 1 |
| Fink, M | 1 |
| Taylor, MA | 1 |
| Lewiston, T | 1 |
| Linnoila, M | 1 |
| Viukari, M | 1 |
| Lamminsivu, U | 1 |
| Auvinen, J | 1 |
| Moleman, P | 1 |
| Schmitz, PJ | 1 |
| Ladee, GA | 1 |
| Romach, M | 1 |
| Busto, U | 1 |
| Somer, G | 1 |
| Kaplan, HL | 1 |
| Sellers, E | 1 |
| Ungvari, GS | 1 |
| Leung, CM | 1 |
| Wong, MK | 1 |
| Lau, J | 1 |
| Goldstein, MZ | 1 |
| Pataki, A | 1 |
| Webb, MT | 1 |
| Schweizer, E | 2 |
| Pohl, R | 1 |
| Balon, R | 1 |
| Fox, I | 2 |
| Rickels, K | 2 |
| Yeragani, VK | 1 |
| Rosebush, PI | 1 |
| Hildebrand, AM | 1 |
| Furlong, BG | 1 |
| Mazurek, MF | 1 |
| Aranko, K | 1 |
| Mattila, MJ | 1 |
| Nuutila, A | 1 |
| Pellinen, J | 1 |
| Dubin, WR | 1 |
| Carboni, MA | 1 |
| Corsa, R | 1 |
| Case, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rapid Tranquilization of Violent or Agitated People in Psychiatric Emergency Settings- A Pragmatic Randomized Controlled Trial of Intramuscular Olanzepine Vs. Intramuscular Haloperidol + Promethazine.[NCT00455234] | Phase 3 | 300 participants | Interventional | 2005-09-30 | Completed | ||
| Multicenter, Randomized Trial on the Effects of Pallidal Deep Brain Stimulation for Tardive Dystonia[NCT00331669] | Phase 2 | 24 participants (Anticipated) | Interventional | 2006-05-31 | Recruiting | ||
| "Interventional Triple-negative Placebo-controlled Personalized Prospective Study Evaluation of the Efficacy and Safety of Noninvasive Neuromodulation of TMS in Subjects With Catatonia"[NCT06176456] | 60 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for lorazepam and Behavior Disorders
| Article | Year |
|---|---|
COVID-19 and catatonia: Prevalence, challenges, pathophysiology, and treatment.
Topics: Catatonia; COVID-19; Electroconvulsive Therapy; Humans; Lorazepam; Mental Disorders; Prevalence | 2023 |
Atypical behavioural effects of lorazepam: clues to the design of novel therapies?
Topics: Attention; Benzodiazepines; Cognition; Drug Discovery; Humans; Lorazepam; Memory; Mental Disorders; | 2010 |
Psychogenic unresponsiveness.
Topics: Autonomic Nervous System Diseases; Consciousness Disorders; Fever; Humans; Hypnotics and Sedatives; | 2011 |
Alcoholism among elderly persons.
Topics: Aged; Alcoholism; Benzodiazepines; Contraindications; Disulfiram; Humans; Incidence; Lorazepam; Ment | 1996 |
Rapid tranquilization: antipsychotics or benzodiazepines?
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clonazepam; Drug Therapy, Combination; Humans; | 1988 |
5 trials available for lorazepam and Behavior Disorders
| Article | Year |
|---|---|
Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine.
Topics: Antipsychotic Agents; Drug Therapy, Combination; Emergencies; Emergency Service, Hospital; Female; H | 2004 |
Efficacy and side effects of lorazepam, oxazepam, and temazepam as sleeping aids in psychogeriatric inpatients.
Topics: Aged; Anti-Anxiety Agents; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Lorazepam; | 1980 |
Lorazepam vs. alprazolam in the treatment of panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Double-Blind Method; Fear; Female; Humans; Lorazepam; Male; Mental D | 1990 |
Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Catatonia; Female; Hospitalization; Humans; Length of St | 1990 |
Lorazepam vs. alprazolam in the treatment of panic disorder.
Topics: Adolescent; Adult; Agoraphobia; Alprazolam; Fear; Female; Humans; Lorazepam; Male; Mental Disorders; | 1988 |
21 other studies available for lorazepam and Behavior Disorders
| Article | Year |
|---|---|
Clinical significance of potential drug-drug interactions in older adults with psychiatric disorders: a retrospective study.
Topics: Aged; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Lorazepam; Mental | 2022 |
Recurrent Catatonia: Infection and Immunity in an Idiopathic Illness.
Topics: Adolescent; Catatonia; Encephalitis; Female; Humans; Lorazepam; Mental Disorders; Olanzapine | 2023 |
Use of Psychotropic Medication During Lactation in Postpartum Psychiatric Patients: Results from an 8-Year Clinical Sample.
Topics: Adult; Breast Feeding; Female; Humans; Lactation; Lorazepam; Mental Disorders; Postpartum Period; Pr | 2020 |
Revisiting lorazepam challenge test: Clinical response with dose variations and utility for catatonia in a psychiatric emergency setting.
Topics: Catatonia; Emergency Service, Hospital; Humans; Lorazepam; Mental Disorders; Psychiatric Status Rati | 2021 |
[Possible malignant neuroleptic syndrome associated with aripiprazole and imipramine and treated with bromocriptine].
Topics: Antipsychotic Agents; Aripiprazole; Bromocriptine; Combined Modality Therapy; Drug Therapy, Combinat | 2013 |
Anti-N-methyl-D-aspartate receptor encephalitis is an important differential diagnosis in acute psychiatric disease.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Anti-Anxiety Agents; Anti-N-Methyl-D-Aspa | 2015 |
[Cushing's disease in a psychiatric setting].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Hypnotics and Sedatives; Lorazepam; Ma | 2017 |
[Catatonia].
Topics: Adult; Catatonia; Female; Humans; Lorazepam; Male; Mental Disorders; Mood Disorders; Psychotic Disor | 2010 |
The use of Pro Re Nata or Statim medications for behavioral control: a summary of experience at a tertiary care children's mental health center.
Topics: Adolescent; Age Factors; Aggression; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Chi | 2011 |
Dexmedetomidine for transport of a spontaneously breathing combative child.
Topics: Child, Preschool; Dexmedetomidine; Humans; Hypnotics and Sedatives; Lorazepam; Male; Mental Disorder | 2012 |
Resistance to changing practice from pro re nata prescriptions to patient group directions in acute mental health settings.
Topics: Adult; Anti-Anxiety Agents; Decision Making; Drug Administration Schedule; Drug Prescriptions; Engla | 2013 |
Opportunity from crisis: how medical cost offset helps our patients and may help save the system.
Topics: Adolescent; Adolescent Behavior; Anti-Anxiety Agents; Drug Overdose; Female; Hospitalization; Humans | 2003 |
Treatment of severe tardive dystonia with pallidal deep brain stimulation.
Topics: Aged; Akathisia, Drug-Induced; Combined Modality Therapy; Deep Brain Stimulation; Female; Globus Pal | 2005 |
Limitations of rapid tranquillisation trial.
Topics: Antipsychotic Agents; Central Nervous System Depressants; Drug Therapy, Combination; Haloperidol; Hu | 2005 |
Catatonia: subtype or syndrome in DSM?
Topics: Amobarbital; Catatonia; Diagnostic and Statistical Manual of Mental Disorders; Humans; Lorazepam; Me | 2006 |
Personal accounts: The system stole my identity.
Topics: Adaptation, Psychological; Anecdotes as Topic; Borderline Personality Disorder; Diagnostic Errors; F | 2007 |
Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics.
Topics: Adolescent; Adult; Age Factors; Aged; Antiparkinson Agents; Basal Ganglia Diseases; Drug Therapy, Co | 1982 |
Clinical aspects of chronic use of alprazolam and lorazepam.
Topics: Alprazolam; Ambulatory Care; Anxiety Disorders; Depressive Disorder; Drug Administration Schedule; F | 1995 |
Benzodiazepines in the treatment of catatonic syndrome.
Topics: Adolescent; Adult; Benzodiazepines; Catatonia; Diazepam; Electroconvulsive Therapy; Female; Humans; | 1994 |
Benzodiazepines, but not antidepressants or neuroleptics, induce dose-dependent development of tolerance to lorazepam in psychiatric patients.
Topics: Administration, Oral; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Dose-Respons | 1985 |
[Therapeutic use of metadoxine in alcohol-related mental and behavioral disorders].
Topics: Adult; Aged; Alcoholism; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Female; Huma | 1987 |